Hicharm Biopharma's Albumin-bound Paclitaxel (Apexelsin®) Sets Sail for EU Market with First Shipment Following EMA Approval

After obtaining EU marketing approval, Haichang Biotech's international strategy has accelerated once again.。8Month10Day，Injectable Paclitaxel (Albumin-Bound) (Apexelsin®, abbreviated as "Albumin Paclitaxel") The first batch of goodsInShandong officially ships outTo the EU,MarksCompanyInEUMarket'sSalesOfficially Launched"The First Shot."

Albumin-bound paclitaxel, as a crucial drug in the field of cancer treatment, has gained widespread clinical recognition due to its excellent clinical safety and patient compliance. It has become one of the mainstream first-line treatments recommended by the European Society for Medical Oncology (ESMO) for metastatic pancreatic cancer and non-small cell lung cancer. In response to the long-standing drug shortage in the European market, Haichang Biotech's successful shipment this timeNot onlyAlleviateCompletedMarket supply and demand tensions，MoreInject New Vitality into Improving Patient Treatment Accessibility.

The Success of Albumin PaclitaxelGoing Global: The Fruit of Deep Collaboration and Joint Efforts Between Haichang Biotech and Industry Leaders Such as Sinovac, CR Double Crane Tiandong Pharmaceutical. The company strictly adheres to EU standards.GMPStandard, EnsureApexelsin®Each batch of products has met the highest international quality standards, thereby successfully obtaining EU market approval and market access permits. This not only demonstrates Haichang Biotech's comprehensive strength in R&D, production, and quality management but also highlights the company's firm determination to provide safe and effective treatment solutions for patients worldwide.

Haichang BiotechCo-President Dr. Meng XiaofengRepresentation：“Apexelsin®The first batch of shipments to the EU is not only an affirmation of our past efforts but also a strong boost for future development. We will continue to adhere to the development strategy of 'innovation-driven, internationalization in parallel,' accelerate the progress of our drug R&D pipeline, and strive to provide more and better treatment options for patients worldwide.SameAt this time, Haichang Biotech will actively expand its international cooperation network, not only deepening strategic collaboration with existing partners in and outside of China, but also seeking to join hands with more like-minded partners to jointly shape an open, inclusive, mutually beneficial, and win-win international development.Pattern. We firmly believe that through the collective wisdom and strength, we can more effectively promote innovation and progress in the global pharmaceutical industry, contributing to the health of humanity worldwide.Strength。”

Looking ahead, Haichang Biotech will stand at a new starting point, continue to deeply cultivate in the biopharmaceutical field, and constantly explore and innovate, striving for more breakthroughs in treatment solutions for cancer and other major diseases. The company will increase R&D investment and focus on cutting-edge technologies.Committed toDevelop more innovative drugs with independent intellectual property rights to provide more precise and effective treatment options for patients worldwide.